A
Ankyra
Developing a platform to significantly improve both the safety and efficacy of cytokine immunotherapies for cancer
About Ankyra
Ankyra Therapeutics is a biotechnology startup that is developing a platform to enhance the safety and effectiveness of cytokine immunotherapies for cancer treatment. Cytokine immunotherapies are powerful immune stimulants used to treat cancer, but their use is often limited due to broad immune activation and toxicity. Ankyra's innovative approach involves localizing cytokines specifically and persistently in tumor tissue, creating intense inflammation hot spots that trigger an anti-tumor immune response. This method is being developed for the treatment of solid tumors.
The company's business model revolves around research and development, with a focus on creating innovative solutions for cancer treatment. Ankyra operates in the biotechnology and healthcare market, serving clients such as hospitals, healthcare providers, and potentially patients suffering from cancer. The company generates revenue through the development and commercialization of its cytokine immunotherapy platform.
Ankyra is led by a team of experienced professionals and scientists, including co-founder and chairman Dr. Tillman Gerngross, and President and CEO Dr. Howard L. Kaufman. The company's scientific advisory board comprises esteemed professionals from institutions such as Harvard Medical School, National Cancer Institute, and the Koch Institute for Integrative Cancer Research at MIT.
In summary, Ankyra Therapeutics is a promising startup in the biotechnology sector, developing innovative solutions to improve cancer treatment. Its unique approach to cytokine immunotherapy could potentially revolutionize the way solid tumors are treated, providing a safer and more effective alternative to current methods.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2021 | $45M | $180M | Polaris Partners · Fidelity Investments · Borealis Ventures · Spring Mountain Capital | — |
| EARLY VCOther financing | May 2020 | $15M | $58M | Undisclosed | — |
Growth signals
Latest recorded traffic for Ankyra is 900 monthly website visits, down 50% over the last three months. Ankyra's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Lucia BioBiotech & Life Sciences |
Brisbane, Australia | Operational | 1 | $1.9M | $7.8M |
Accipiter BiosciencesBiotech & Life Sciences |
Seattle, United States | Operational | |||
ElephasA live tumor imaging company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development |
Garrett Park, United States | Operational | |||
DIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome |
London, United Kingdom | Operational | |||
ResBioticMobilizing an ecosystem of support for the world inside the lungs |
Birmingham, United States | Operational | |||
FecundisSperm-enhancing technologies increasing infertility treatment success |
Rosario, Argentina | Operational | |||
Human Life CORDUmbilical cord-derived allogeneic cell therapy development |
Tokyo, Japan | Operational | |||
Vital BioPoint-of-care blood testing for rapid diagnostic results |
Mississauga, Canada | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ankyra in the Cambridge ecosystem
The Ankyra office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Polaris Partners
Fidelity Investments- BVBorealis Ventures
Spring Mountain Capital
Mithril
Other known investors1 additional known investor
Massachusetts Institute of Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ankyra on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ankyra’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










